Genocea Biosciences (GNCA) Competitors

Calithera Biosciences (NASDAQ:CALA) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

Which has higher valuation & earnings, CALA or GNCA?

Genocea Biosciences has higher revenue and earnings than Calithera Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calithera Biosciences	N/A	N/A	-$39.65M	N/A	N/A
Genocea Biosciences	$1.91M	0.00	-$33.20M	-$0.61	N/A

Does the MarketBeat Community favor CALA or GNCA?

Genocea Biosciences received 47 more outperform votes than Calithera Biosciences when rated by MarketBeat users. Likewise, 55.43% of users gave Genocea Biosciences an outperform vote while only 55.09% of users gave Calithera Biosciences an outperform vote.

Company	Underperform	Outperform
Calithera Biosciences	Outperform Votes 341 55.09%	Underperform Votes 278 44.91%
Genocea Biosciences	Outperform Votes 388 55.43%	Underperform Votes 312 44.57%

Does the media favor CALA or GNCA?

In the previous week, Calithera Biosciences' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company	Overall Sentiment
Calithera Biosciences	Neutral
Genocea Biosciences	Neutral

Which has more risk and volatility, CALA or GNCA?

Calithera Biosciences has a beta of -2.56, meaning that its share price is 356% less volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.

Is CALA or GNCA more profitable?

Calithera Biosciences' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calithera Biosciences	N/A	N/A	N/A
Genocea Biosciences	N/A	-182.88%	-62.76%

Do institutionals & insiders hold more shares of CALA or GNCA?

0.6% of Genocea Biosciences shares are owned by institutional investors. 6.6% of Calithera Biosciences shares are owned by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Genocea Biosciences beats Calithera Biosciences on 6 of the 9 factors compared between the two stocks.